Predictive biomarkers for acute gallstone pancreatitis in the pediatric population

Maisam Abu-El-Haija^{a,1}, Tom K. Lin^{a,1}, Soofia Khan^a, Lin Fei^{a,b}, Tyler Thompson^a, and Jaimie D. Nathan^{c,*}

^aDivision of Pediatric Gastroenterology Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

^bDivision of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, USA

^cDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

Abstract

Background: Early biomarkers for diagnosis of gallstone pancreatitis (GP) in pediatrics have not been well studied. Reliably differentiating GP from other causes of acute pancreatitis (AP) would allow for early diagnosis and prompt management. We sought to assess biomarkers and clinical variables for early GP diagnosis from a prospectively-enrolled registry of pediatric patients presenting with first AP episode.

Methods: Cross-sectional analysis of a prospective acute pancreatitis registry of children enrolled from March 2013 through October 2016 was performed. Fisher's exact test and Wilcoxon rank sum test were used to compare demographic and clinical variables between GP and non-GP groups. A multivariable logistic regression model was derived, and receiver operating characteristic (ROC) curve was built using stepwise selection.

Results: 114 subjects were enrolled (21 with GP, 93 as non-GP). Median was statistically higher for GP patients in lipase values X upper limit of normal (ULN) on admission, weight percentile

*Corresponding author. Cincinnati Children's Hospital Medical Center, Division of Pediatric General and Thoracic Surgery, MLC 2023, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, United States. jaimie.nathan@cchmc.org (J.D. Nathan).

¹Co-First authors.

Authorship

Maisam Abu-El-Haija made substantial contributions to the conception or design of the work and the acquisition, analysis, and interpretation of data, drafted the work and revised it critically for important intellectual content, and gave final approval of the version to be published. Tom K. Lin made substantial contributions to the conception or design of the work and the acquisition, analysis, and interpretation of data, drafted the work and revised it critically for important intellectual content, and gave final approval of the version to be published. Soofia Khan made substantial contributions to the acquisition, analysis, and interpretation of data, revised it critically for important intellectual content, and gave final approval of the version to be published. Lin Fei made substantial contributions to the acquisition, analysis and interpretation of data, revised it critically for important intellectual content, and gave final approval of the version to be published. Tyler Thompson made substantial contributions to the acquisition, analysis, and interpretation of data, revised it critically for important intellectual content, and gave final approval of the version to be published. Jaimie D. Nathan made substantial contributions to the conception or design of the work and the analysis and interpretation of data, revised it critically for important intellectual content, and gave final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Disclosure Statement: The authors report no conflicts of interest.

Presented at: European Society for Pediatric Gastroenterology, Hepatology and Nutrition, Prague, Czech Republic, May 2017.

for age, alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase. By multivariable analysis, significant predictors were ALT and Lipase xULN. A model built using these two variables for prediction of GP identified an AUROC of 0.85. At a predictive probability of 0.35, the model had an 80% sensitivity, 93% specificity, 76% positive predictive value and 95% negative predictive value.

Conclusions: We have developed a model for predicting GP in children that could help guide clinical management of AP patients. Future studies are needed to validate use of laboratory findings and clinical variables in evaluation of gallstone etiology in pediatric AP patients.

Keywords

Acute pancreatitis; Gallstone pancreatitis; Pediatrics; Predictive modeling

1. Introduction

Recent reports have shown a rising incidence of pediatric acute pancreatitis (AP), currently estimated to be up to 1:10,000 [1]. One of the most common AP etiologies in adult patients is gallstone pancreatitis (GP), occurring in up to 40% of cases [2]. In children, gallstone disease is a less common etiology for AP, occurring in 10-30% of cases [3,4], but it remains an important pathology for early recognition. According to the International Association of Pancreatology/American Pancreatic Association (IAP/APA) adult-based guidelines, a cholecystectomy performed during the index admission is recommended in GP patients to minimize disease recurrence and complications [5]. The same management guidelines call for urgent endoscopic retrograde cholangiopancreatography (ERCP) in cases of suspected cholangitis [5]. Etiology-guided intervention for GP has been similarly studied in children, with findings of improved patient outcomes including prevention of readmissions due to symptom recurrence when a cholecystectomy is performed during the index admission [6]. These evidence-based best practices highlight the benefit of early GP detection. However, to date there have been limited studies that have attempted to elucidate specific patient characteristics or diagnostic predictors of GP in the pediatric population.

Adult studies have investigated the role of biochemical markers in early diagnosis of GP. The use of amylase and alanine aminotransferase (ALT) to predict GP in patients with high human immunodeficiency virus (HIV) prevalence has been previously investigated [7]. Others have reported the use of liver enzyme elevations in the diagnosis or prediction of GP, including a meta-analysis of hepatic profile parameters [8,9]. The use of ultrasonography (US) with or without liver enzyme elevation has shown favorable results in the diagnosis of GP in adults early in the course of the disease [10,11]. Such investigative efforts focused on the pediatric age group have been limited. Retrospective studies have reported on risk factors associated with biliary pancreatitis in children [12,13], as well as a study by Coffey et al. which utilized a triad of gamma-glutamyl transpeptidase (GGT), ALT and lipase within 48 h of presentation as clinical predictors of biliary pancreatitis in children [14]. Prompt differentiation of GP from other causes of AP in children poses significant implications including timely management and intervention in an effort to limit patient morbidity.

Our study aim was to investigate biochemical and clinical variables for early GP diagnosis in a prospectively-enrolled registry of pediatric patients presenting with their first occurrence of AP. A secondary aim was to assess the frequency of radiologic imaging in the accurate diagnosis GP.

2. Methods

The study was approved by the Institutional Review Board (2012–4050) at Cincinnati Children's Hospital Medical Center (Cincinnati, Ohio). As per institutional protocol, consent from the parent or legal guardian and assent (for subjects over 11-years-old) was obtained for all enrollees <21-years-old presenting with their first occurrence of AP. The diagnosis of AP was based on achievement of at least 2 of 3 criteria: (1) abdominal pain suggestive of or compatible with pancreatitis, (2) serum amylase or lipase level at or above three times the upper limit of normal, and (3) radiographic findings consistent with acute pancreatitis. Those families and subjects agreeing to inclusion within the registry were prospectively enrolled.

A forty-two month (March 2013 thru October 2016) cross-sectional analysis of the registry was performed. AP cases with an etiology determined to be unrelated to gallstone pathology were classified as *non-GP*. These secondary causes of AP included viral, systemic illness, drug-induced, metabolic, congenital anomalies, trauma or idiopathic. A GP diagnosis was based on documentation of gallstone(s) or sludge within the gallbladder and/or common bile duct (CBD), or CBD dilation in the presence of elevated liver enzymes, by radiographic imaging (transabdominal US, computed tomography, magnetic resonance imaging, fluoroscopy during ERCP) performed during the AP presentation in the absence of identification of an alternative cause for AP.

2.1. Statistical analysis

Fisher's exact test and Wilcoxon rank sum test were used to compare demographic and clinical variables between GP and non-GP groups. In order to optimize prediction of GP, a multivariable logistic regression model was derived based on variables from the univariate analysis with a *p* value up to 0.2 and others known from the medical literature to be predictive, including exclusion based on potential collinearity, and the Area Under Receiver Operating Characteristic Curve (AUROC) was built using stepwise selection. A *p*-value was considered significant when <0.05. Statistical analyses were conducted using SAS® 9.3 software.

3. Results

Within the forty-two month study period, 114 patients were enrolled into the AP registry. Twenty-one (18%) subjects were categorized as having a GP etiology, with the remaining 93 subjects grouped into non-GP etiology. All GP subjects underwent at least one form of radiographic imaging with an etiology of GP being confirmed by ultrasound 21/21 (100%), CT 3/3 (100%), and MRCP 5/7 (71%). Abnormal biliary imaging findings included stone/sludge within the gallbladder and/or CBD, and intrahepatic and/or extrahepatic biliary dilation. In 9 patients, initial evaluation by laboratories and imaging was followed by ERCP due to concern for ongoing CBD obstruction. In 4/9 ERCP procedures, CBD stone/sludge

was identified, prompting endoscopic therapeutic intervention of a biliary sphincterotomy with stone/sludge extraction. In the remaining 5 patients in which stone/sludge was not found within the biliary tree, it was presumed the obstructing material had spontaneously passed prior to performance of the ERCP. Endoscopic ultrasound (EUS) was not performed on any of the enrolled subjects.

3.1. GP versus non-GP cases

Univariate comparison of GP to non-GP subjects found no significant differences in gender, age distribution, initial amylase elevation X upper limit of normal (ULN), creatinine or total bilirubin (Table 1). Univariate analysis of median values between GP and non-GP subjects were found to be statistically higher for GP patients in: lipase x ULN ($p < 0.004$), weight percentile for age ($p < 0.038$), ALT ($p < 0.001$), aspartate aminotransferase (AST) ($p < 0.001$), gamma-glutamyl transferase (GGT) ($p < 0.001$) (Table 1).

From the multivariable analysis, ALT was significant when comparing GP to non-GP subjects ($p < 0.001$), while lipase x ULN nearly reached statistical significance ($p = 0.059$) (Table 2).

3.2. GP prediction model for pediatric AP

As represented in Fig. 1, using ALT and lipase for prediction of GP identified an AUROC of 0.8545 (0.7468, 0.9623). An ALT only model produced an AUROC of 0.8679 (0.7691, 0.9666), and a lipase only model produced an AUROC of 0.6877 (0.5457, 0.8297). There were 97 patients with complete data used to build the model for GP prediction on admission.

At a predictive probability of 0.35, the statistical model was associated with sensitivity of 80%, specificity of 93%, positive predictive value (PPV) of 76%, and negative predictive value (NPV) of 95%.

4. Discussion

In this study, we report GP to encompass approximately 18% of all first AP attacks in children, which represents the first study to highlight the role of GP in pancreatitis from a prospective dataset in children. Reliable diagnostic testing for GP can be invaluable given the identified benefits from early therapies that may limit patient morbidity related to delayed recognition. Moreover, the avoidance of invasive interventions (e.g., ERCP, cholecystectomy) is an equally desirable outcome in those patients without a biliary etiology where such therapies would provide no such utility. Limited adult studies have primarily shown that an elevated ALT is predictive of biliary origin in AP with a PPV of 81–95% [9,11,15,16]. Radiologic imaging alone, specifically ultrasound, has its own limitations in the diagnosis of GP with a sensitivity of 67–87% for cholecystolithiasis and a lower sensitivity of 20–50% for choledocholithiasis [17]. Similar studies focused on pediatric GP have been limited. Retrospective studies in children have reported on liver profile abnormalities as risk factors for biliary pancreatitis in children [12,13]. In another retrospective study, Coffey et al. reported on the use of a triad of an elevated GGT, ALT and lipase within 48 h of presentation as predictors of biliary pancreatitis in children; however, the cohort of biliary pancreatitis included only 11 patients with gallstones, with others

included with choledochal cysts and pancreas divisum, creating a heterogeneous cohort [14]. An additional limitation of the study was incomplete data due to its retrospective nature.

By means of a prospectively-enrolled pediatric registry of patients presenting with their first occurrence of AP, we derived a model that appears to be capable of predicting GP at time of admission. To our knowledge, the use of the combination of ALT and lipase elevation has not been previously reported for diagnosing GP in children. As indicated by the AUROC for ALT and the model that combines ALT with lipase, the ALT performs well for the prediction without the inclusion of lipase. We elected to include lipase within the model in this initial stage until it is further validated, as lipase is a non-invasive biochemical test obtained in most, if not all, cases of AP on presentation and in our model provided additive predictive probability of GP with improved specificity and PPV of the prediction compared to the model without lipase. PPV and specificity of the model with ALT only were 65% and 88%, while in a model with lipase, PPV and specificity were 76% and 93%, respectively. Sensitivity and NPV did not differ with and without lipase in the model.

In this cohort, transabdominal US was utilized as the standard for the diagnosis of biliary pancreatitis. In a high percentage of GP subjects (56%), ERCP failed to find stone/sludge at time of the procedure, and these patients were considered cases of spontaneous stone/sludge migration. This may be explained by variability in the timing of GP diagnosis relative to ERCP intervention. However, the frequency and timing of possible stone migration, as well as clinical factors that may influence the probability of spontaneous passage, is unknown in the pediatric population. In one study of adult patients with EUS-documented choledocholithiasis, stone migration was observed in 21% of cases within 1 month based on the absence of stone findings at time of subsequent ERCP [18]. Gallbladder in situ and stone diameter size <8 mm were identified factors to favorably influence stone migration. A stone size approaching 8 mm would be highly unexpected in a child or adolescent, and whether an intact gallbladder or other factors impact stone migration in the pediatric age group remains unknown.

While this study reports new findings, it has some limitations mainly in the relatively small sample size, in the fact that the tool was built on data collected from a registry, and by virtue of the absence of a validation cohort. In addition, the fact that no absolute non-invasive gold standard test exists for the diagnosis of GP is an inherent limitation in our study attempt at identifying a predictive biochemical marker. When weighing the cost-effectiveness of specific testing to invasive investigation that may provide a high sensitivity and specificity, perhaps a feasible diagnostic option is EUS. EUS has been shown to possess sensitivity and specificity scores of 84–97% and 95–100%, respectively, in the detection of choledocholithiasis [19–22]. EUS so far has limited use in pediatric pancreatitis. Further studies may show benefit of EUS in biliary pancreatitis and in the detection of microlithiasis, and this will be best paired with clinical predictive models to help guide which patient groups would benefit most from this intervention.

In conclusion, GP is a significant etiology in children presenting with their first occurrence of AP. Early recognition through highly predictive biochemical markers may be achieved using a model incorporating ALT and lipase elevation. Further studies to validate our

findings are necessary to support of the use of this model in the clinical setting for children with AP.

References

- [1]. Morinville VD, Barmada MM, Lowe ME. Increasing incidence of acute pancreatitis at an American pediatric tertiary care center: is greater awareness among physicians responsible? *Pancreas* 2010;39:5–8. [PubMed: 19752770]
- [2]. Forsmark CE, Baillie J, Practice AGAIC, Economics C, Board AGAIGAGA. Institute technical review on acute pancreatitis. *Gastroenterology* 2007;132:2022–44. [PubMed: 17484894]
- [3]. Szabo FK, Fei L, Cruz LA, Abu-El-Haija M. Early enteral nutrition and aggressive fluid resuscitation are associated with improved clinical outcomes in acute pancreatitis. *J Pediatr* 2015;167:397–402. e1. [PubMed: 26210842]
- [4]. Bai HX, Lowe ME, Husain SZ. What have we learned about acute pancreatitis in children? *J Pediatr Gastroenterol Nutr* 2011;52:262–70. [PubMed: 21336157]
- [5]. Working Group IAPAAPAG. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatolgy* 2013;13:e1–15. [PubMed: 24054878]
- [6]. Lin TK, Palermo JJ, Nathan JD, Tiao GM, Hornung LN, Fei L, et al. Timing of cholecystectomy in children with biliary pancreatitis. *J Pediatr Gastroenterol Nutr* 2016;62:118–21. [PubMed: 26308314]
- [7]. Moolla Z, Anderson F, Thomson SR. Use of amylase and alanine transaminase to predict acute gallstone pancreatitis in a population with high HIV prevalence. *World J Surg* 2013;37:156–61. [PubMed: 23015223]
- [8]. Dholakia K, Pitchumoni CS, Agarwal N. How often are liver function tests normal in acute biliary pancreatitis? *J Clin Gastroenterol* 2004;38:81–3. [PubMed: 14679333]
- [9]. Tenner S, Dubner H, Steinberg W. Predicting gallstone pancreatitis with laboratory parameters: a meta-analysis. *Am J Gastroenterol* 1994;89:1863–6. [PubMed: 7942684]
- [10]. Wang SS, Lin XZ, Tsai YT, Lee SD, Pan HB, Chou YH, et al. Clinical significance of ultrasonography, computed tomography, and biochemical tests in the rapid diagnosis of gallstone-related pancreatitis: a prospective study. *Pancreas* 1988;3:153–8. [PubMed: 3287369]
- [11]. Anderson K, Brown LA, Daniel P, Connor SJ. Alanine transaminase rather than abdominal ultrasound alone is an important investigation to justify cholecystectomy in patients presenting with acute pancreatitis. *HPB* 2010;12: 342–7. [PubMed: 20590910]
- [12]. Choi BH, Lim YJ, Yoon CH, Kim EA, Park YS, Kim KM. Acute pancreatitis associated with biliary disease in children. *J Gastroenterol Hepatol* 2003;18: 915–21. [PubMed: 12859720]
- [13]. Ma MH, Bai HX, Park AJ, Latif SU, Mistry PK, Pashankar D, et al. Risk factors associated with biliary pancreatitis in children. *J Pediatr Gastroenterol Nutr* 2012;54:651–6. [PubMed: 22002481]
- [14]. Coffey MJ, Nightingale S, Ooi CY. Predicting a biliary aetiology in paediatric acute pancreatitis. *Arch Dis Child* 2013;98:965–9. [PubMed: 24013807]
- [15]. Liu CL, Fan ST, Lo CM, Tso WK, Wong Y, Poon RT, et al. Clinico-biochemical prediction of biliary cause of acute pancreatitis in the era of endoscopic ultrasonography. *Aliment Pharmacol Ther* 2005;22:423–31. [PubMed: 16128680]
- [16]. Levy P, Boruchowicz A, Hastier P, Pariente A, Thevenot T, Frossard JL, et al. Diagnostic criteria in predicting a biliary origin of acute pancreatitis in the era of endoscopic ultrasound: multicentre prospective evaluation of 213 patients. *Pancreatolgy* 2005;5:450–6. [PubMed: 15985771]
- [17]. Alexakis N, Lombard M, Raraty M, Ghaneh P, Smart HL, Gilmore I, et al. When is pancreatitis considered to be of biliary origin and what are the implications for management? *Pancreatolgy* 2007;7:131–41. [PubMed: 17592225]
- [18]. Frossard JL, Hadengue A, Amouyal G, Choury A, Marty O, Giostra E, et al. Choledocholithiasis: a prospective study of spontaneous common bile duct stone migration. *Gastrointest Endosc* 2000;51:175–9. [PubMed: 10650260]

- [19]. Canto MI, Chak A, Stellato T, Sivak MV, Jr. Endoscopic ultrasonography versus cholangiography for the diagnosis of choledocholithiasis. *Gastrointest Endosc* 1998;47:439–48. [PubMed: 9647366]
- [20]. Palazzo L, O'Toole D. EUS in common bile duct stones. *Gastrointest Endosc* 2002;56:S49–57. [PubMed: 12297749]
- [21]. Amouyal P, Amouyal G, Levy P, Tuzet S, Palazzo L, Vilgrain V, et al. Diagnosis of choledocholithiasis by endoscopic ultrasonography. *Gastroenterology* 1994;106:1062–7. [PubMed: 8143973]
- [22]. Tse F, Liu L, Barkun AN, Armstrong D, Moayyedi PEUS. A meta-analysis of test performance in suspected choledocholithiasis. *Gastrointest Endosc* 2008;67:235–44. [PubMed: 18226685]

Fig. 1.
Prediction Model for Gallstone pancreatitis using ALT and Lipase elevation x ULN. Sample size n = 97 patients.

Table 1

Univariate comparison between Gallstone and Non-gallstone pancreatitis patients.

Variable	Gallstone pancreatitis (n = 21)	Non-gallstone pancreatitis (n = 93)	p-value
Age	15.2 (13.6, 16.2)	12.7 (8.92, 15.9)	0.074
Gender (F)	13 (61.9%)	42 (45.2%)	0.227
Weight %	86.1 (39.3, 98.4) n=19	46.8 (19.5, 82) n=91	0.015
BMI %	79.8 (36.4, 98) n=17	58 (23.1, 88) n=88	0.038
WBC	10.5 (5.2, 12.9) n = 17	10.9 (8, 17.3) n = 61	0.162
Creatinine	0.63 (0.55, 0.67) n = 16	0.53 (0.4, 0.65) n = 72	0.161
Lipase x ULN	31.3 (8.37, 78.4) n=20	7.15 (3.83, 17) n=90	0.004
Amylase x ULN	4.12 (0.69, 17.5) n = 14	2.06 (1.05, 4.21) n = 69	0.219
T Bilirubin	0.7 (0.3, 1) n = 13	0.6 (0.3, 1.35) n = 60	0.977
GGT	411 (197, 650) n=11	29 (13, 111) n=33	0.001
ALT	302 (168, 441) n=21	26 (20, 59) n=77	0.001
AST	170 (118, 260) n=21	33 (20, 58) n=77	0.001
SAP	2 (9.52%)	11 (11.8%)	1.000

Data presented as median (25th, 75th percentile) or frequency (%).

Wilcoxon rank sum test for continuous variables. All other categorical variables are tested with Fisher's exact test.

BMI, body mass index; WBC, white blood cell count; ULN, upper limit of normal; T bilirubin, total bilirubin; GGT, gamma-glutamyl transferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SAP, severe acute pancreatitis.

Table 2

Odd ratios estimates for Lipase elevation and ALT and risk of gallstone pancreatitis (n = 97).

Effect	Odds Ratio Estimate	95% Confidence Limits	p-value
ALT	11.832	(3.779, 37.050)	<0.001
Lipase x ULN	2.931	(0.960, 8.946)	0.059